Vistagen Therapeutics (VTGN) Cash & Current Investments (2011 - 2026)

Vistagen Therapeutics has reported Cash & Current Investments for 15 years, with the latest figure at $45.4 million in Q1 2026.

• Quarterly Cash & Current Investments fell 43.59% year-over-year to $45.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $45.4 million (down 43.59% YoY) and the FY2026 annual result came in at $45.4 million, down 43.59% from the prior year.
• Cash & Current Investments declined to $45.4 million in Q1 2026 per VTGN's latest filing, from $61.8 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $126.6 million in Q4 2023 and troughed at $9.6 million in Q2 2023.
• A 5-year average of $65.4 million and a median of $63.2 million in 2025 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2023 and 2024: Cash & Current Investments sank 81.53% in 2023, then jumped 1028.79% in 2024.
• Over 5 years, Cash & Current Investments stood at $25.0 million in 2022, then jumped by 406.4% to $126.6 million in 2023, then plunged by 30.05% to $88.6 million in 2024, then plunged by 30.25% to $61.8 million in 2025, then decreased by 26.5% to $45.4 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $45.4 million, $61.8 million, and $77.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.